Cancer antigen 125 concentrations in patients on chronic peritoneal dialysis: Relationship with dialysis quality and membrane transport properties
| Autor: | Jasna Trbojević-Stanković, Dejan Nesic, Nataša Ž. Jovanović, Radmila Obrenović, Biljana Stojimirovic, Novica Boricic |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
ACE inhibitors medicine.medical_treatment 0206 medical engineering Peritonitis 02 engineering and technology Peritoneal equilibration test Gastroenterology General Biochemistry Genetics and Molecular Biology Peritoneal dialysis statins chemistry.chemical_compound Internal medicine Medicine Prospective cohort study lcsh:QH301-705.5 Dialysis Creatinine business.industry 021001 nanoscience & nanotechnology medicine.disease 020601 biomedical engineering 3. Good health cancer antigen 125 chemistry peritoneal dialysis lcsh:Biology (General) Erythropoietin Erythropoiesis erythropoietin 0210 nano-technology General Agricultural and Biological Sciences business medicine.drug |
| Zdroj: | Archives of Biological Sciences, Vol 70, Iss 1, Pp 13-20 (2018) |
| ISSN: | 1821-4339 0354-4664 |
| Popis: | The aim of this study was to evaluate longitudinal changes in drained dialysate cancer antigen 125 (dCA-125) levels and to assess relationships between dCA-125 and dialysis quality, peritoneal membrane transport rates, dialysate glucose load, peritonitis and use of erythropoiesis stimulating agents (ESA), angiotensin-converting-enzyme inhibitors (ACEi) and statins in patients with end-stage renal failure during the first 6 months of peritoneal dialysis (PD) treatment. This prospective study included 20 patients (11 males and 9 females; mean age 62.90±12.69 years) who were followed-up during the first 6 months of PD using conventional low pH glucose-based dialysis fluids. The concentration of dCA-125 was measured in all patients, and the peritoneal equilibration test (PET), peritoneal dialysis treatment adequacy (Kt/V), normalized protein catabolic rate (nPCR), and total, peritoneal and residual clearances of urea and creatinine were calculated. Information on peritonitis occurrence, the use of ESA, ACEi and statins were collected. Data were analyzed by the Mann-Whitney test, Wilcoxon matched pairs test and Spearman’s rank correlation. The concentration of dCA-125 significantly decreased during the follow-up (p=0.016). After 6 months of PD treatment, the concentration of dCA-125 decreased significantly (p=0.016) in all patients. The decrease was present in all patients, but was statistically significant in patients on ACEi therapy (p=0.006) and in patients not using statins (p=0.005) or ESA (p=0.012). No correlation was found between dCA-125 and glucose load, but a statistically significant negative correlation between dCA-125 and the PET for creatinine was observed (p=0.013). These findings challenge the role of dCA-125 in predicting mesothelial cell integrity in PD patients. https://doi.org/10.2298/ABS170324021J Received: March 24, 2017; Revised: May 7, 2017; Accepted: May 9, 2017; Published onlione: June 12, 2017 How to cite this article: Jovanovic NŽ, Trbojevic-Stankovic JB, Nesic DM, Obrenovic RŽ, Boricic NI, Stojimirovic BB. Cancer antigen 125 concentrations in patients on chronic peritoneal dialysis: Relationship with dialysis quality and membrane transport properties. Arch Biol Sci. 2018;70(1):13-20. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|